Back to Search Start Over

Pro: Oximes should be used routinely in organophosphate poisoning.

Authors :
Thiermann, Horst
Worek, Franz
Source :
British Journal of Clinical Pharmacology. Dec2022, Vol. 88 Issue 12, p5064-5069. 6p.
Publication Year :
2022

Abstract

In poisoning with organophosphorus compounds (OP), patients can only profit from the regeneration of acetylcholinesterase, when the poison load has dropped below a toxic level. Every measure that allows an increase of synaptic acetylcholinesterase (AChE) activity at the earliest is essential for timely termination of the cholinergic crisis. Only drug‐induced reactivation allows fast restoration of the inhibited AChE. Obidoxime and pralidoxime have proved to be able to reactivate inhibited cholinesterase thereby saving life of poisoned animals. A plasma level of obidoxime or pralidoxime allowing reactivation in humans poisoned by OP can be adjusted. There is no doubt that obidoxime and pralidoxime are able to reactivate OP‐inhibited AChE activity in poisoned patients, thereby increasing AChE activity and contributing substantially to terminate cholinergic crisis. Hence, a benefit may be expected when substantial reactivation is achieved. A test system allowing determination of red blood cell AChE activity, reactivatability, inhibitory equivalents and butyrylcholinesterase activity is available for relatively low cost. If any reactivation is possible while inhibiting equivalents are present, oxime therapy should be maintained. In particular, when balancing the benefit risk assessment, obidoxime or palidoxime should be given as soon as possible and as long as a substantial reactivation may be expected. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03065251
Volume :
88
Issue :
12
Database :
Academic Search Index
Journal :
British Journal of Clinical Pharmacology
Publication Type :
Academic Journal
Accession number :
160233194
Full Text :
https://doi.org/10.1111/bcp.15215